Cart
sales@molnova.com
2,2-Dimethyl-5-(2,5-xylyloxy)valeramide
CAS No. 114413-97-7
2,2-Dimethyl-5-(2,5-xylyloxy)valeramide( 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamide )
Catalog No. M28379 CAS No. 114413-97-7
2,2-Dimethyl-5-(2,5-xylyloxy)valeramide is a chemical compound.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 35 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 43 | In Stock |
|
| 25MG | 73 | In Stock |
|
| 50MG | 107 | In Stock |
|
| 100MG | 160 | In Stock |
|
| 200MG | 241 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name2,2-Dimethyl-5-(2,5-xylyloxy)valeramide
-
NoteResearch use only, not for human use.
-
Brief Description2,2-Dimethyl-5-(2,5-xylyloxy)valeramide is a chemical compound.
-
Description2,2-Dimethyl-5-(2,5-xylyloxy)valeramide is a chemical compound.
-
In Vitro——
-
In Vivo——
-
Synonyms5-(2,5-dimethylphenoxy)-2,2-dimethylpentanamide
-
PathwayOthers
-
TargetOther Targets
-
RecptorNa+/H+-exchanger (NHE)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number114413-97-7
-
Formula Weight249.354
-
Molecular FormulaC15H23NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1ccc(C)c(OCCCC(C)(C)C(N)=O)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Timothy A. Ayers, et al. Process for preparing 2-chloro-3n-(2-benzimidazolyl)-4-methyl-3-thienylamine useful as a sodium/proton exchanger type 3 inhibitor. WO2011019784A1
molnova catalog
related products
-
L-822179
L-822179 (α5IA) is a selective inverse agonist for the Α5 subtype of GABAA receptor with higher intrinsic activity at the A5 subtype than other drugs.
-
2-CHLOROMETHYL-1,1-D...
2-CHLOROMETHYL-1,1-DIOXO-1,2-DIHYDRO-1LAMBDA*6*-BENZO[D]ISOTHIAZOL-3-ONE targets the Neutrophil elastase (human).
-
JHU-083
JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b+ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals.
